<DOC>
	<DOCNO>NCT02429973</DOCNO>
	<brief_summary>Multicenter prospective phase II trial gemcitabine rapamycin second line metastatic osteosarcoma . The study include 6 cycle combination gemcitabine+rapamycin metastatic unresectable osteosarcoma patient .</brief_summary>
	<brief_title>Trial With Gemcitabine Rapamycin Second Line Metastatic Osteosarcoma</brief_title>
	<detailed_description>The trial seek analyze progression free survival ( PFS ) , measure PFS rate 4 month , patient metastatic osteosarcoma previously receive active drug disease ( methotrexate , cisplatin , adriamycin ifosfamide ) . The treatment schedule consist maximum 6 cycle 3 week gemcitabine+rapamycin . Gemcitabine give 800 mg/m2 day 1 8 cycle 21 day . Rapamycin give 5 mg per day treatment duration .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Informed consent sign trial test Age equal less 80 year Histological diagnosis highgrade , metastatic unresectable osteosarcoma progression Previous treatment drug use first line : methotrexate , adriamycin , platinum Measurable disease , acoording RECIST criterion ECOG 02 Patients irradiated target lesion ECOG &gt; 2 Bilirubin level normal value . Creatinine 1.6 mg/dL History cancer except basal cell cancer cervical cancer adequately treat Serious cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Osteosarcoma</keyword>
</DOC>